Person profile

Public information reviewed

Jon Congleton

Role

President and Chief Executive Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Board role

President and Chief Executive Officer and Director · Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Board role

Director · Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

Director · Current mandate

Executive · Ceo · Enterprise Leadership
FollowSave PDF
More
Reports & analysisAlpha Eval
Public sources
4 reviewed
Profile ownership
Not yet claimed
Last reviewed
Sep 6, 2026
View sources

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
41 current organization shown on this profile
Board positions
11 supported by public sources, 0 supplied by the profile owner
Committee roles
Not establishedNo committee role is currently confirmed by the cited sources
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Alpha has not published a narrative summary because the current public source set is not sufficient.

Current roles

Appointments & responsibilities

Executive appointments

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Connections

Explore the roles, education and affiliations published in this record.

Mineralys Therapeutics, Inc.

Open Mineralys Therapeutics, Inc. profile →

President and Chief Executive Officer at Mineralys Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-12

President and Chief Executive Officer and Director at Mineralys Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-12

Director at Mineralys Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-12

Chief Executive Officer at Mineralys Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-12

Mineralys Therapeu…Mineralys Therapeutics, Inc.Jon Congleton

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec Form OwnershipPublic profile sourceSupports Director at Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Chief Executive Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS).Open sourceSource 2 · Sec Def 14aPublic profile sourceSupports President and Chief Executive Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS), President and Chief Executive Officer and Director at Mineralys Therapeutics, Inc. (NASDAQ: MLYS), Executive title, Board membership.Open sourceSource 3 · Sec FilingMLYS 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:jon-congleton-mlys
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

AI expertise · Source reportedAI expertise: not identified in the cited filing1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

AI governance relevance · Source reportedAI governance relevance reported from role and filings1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Mineralys Therapeutics, Inc.1 source
Verification
Source reported
Confidence
95%
Last reviewed
Sep 6, 2026
Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Executive company · CorroboratedExecutive at Mineralys Therapeutics, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive function · Source reportedEnterprise Leadership (CEO)1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 3, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Executive title · Source reportedExecutive title: President and Chief Executive Officer1 source
Verification
Source reported
Confidence
95%
Last reviewed
Sep 6, 2026
Executive title · CorroboratedExecutive title: President, Chief Executive Officer, and DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

View all sources4 records
  1. https://www.sec.gov/Archives/edgar/data/1933414/000193341426000100/wk-form4_1784163491.xml

    Sec Form Ownership · Tier not stated · Reviewed Jul 29, 2026

    Supports: Director at Mineralys Therapeutics, Inc. (NASDAQ: MLYS) · Chief Executive Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

  2. https://www.sec.gov/Archives/edgar/data/1933414/000193341426000069/mlys-20260408.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: President and Chief Executive Officer at Mineralys Therapeutics, Inc. (NASDAQ: MLYS) · President and Chief Executive Officer and Director at Mineralys Therapeutics, Inc. (NASDAQ: MLYS) · Executive title · Board membership

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: AI expertise · AI governance relevance · Executive company · Executive function · Executive title